Differences between Avatrombopag (Sucoxin) and Hatrombopag and Reference for Clinical Selection

Avatrombopag (Avatrombopag) and Hetrombopag (Hetrombopag) are both oral thrombopoietin receptor agonists (TPO-RA), mainly used to treat thrombocytopenia related to chronic liver disease and specific types of immune thrombocytopenia (ITP). The common mechanism of action of the two is to promote the proliferation and differentiation of bone marrow megakaryocytes by activating the thrombopoietin receptor (c-Mpl), thereby increasing the number of platelets and reducing the risk of bleeding. However, there are still some differences in pharmacological properties, indications and clinical use.

Avatrombopag is characterized by rapid oral absorption, high bioavailability, and is not significantly affected by food. It is suitable for daily long-term management of patients with thrombocytopenia. Its clinical application mainly focuses on platelet elevation before invasive procedures in patients with chronic liver disease and platelet maintenance therapy in ITP patients. In comparison, heltrombopag may be slightly inferior to avatrombopag in terms of pharmacokinetics, and the dosage is closely related to individual differences, and the dosage needs to be dynamically adjusted based on platelet count.

In terms of safety, the side effects of avatrombopag are usually mild to moderate, such as headache, fatigue, gastrointestinal discomfort, etc., and the risk of thrombosis is relatively low. Hatrombopag also has similar side effects, but some studies have shown that there may be a risk of thrombosis at high doses or long-term use, requiring more stringent monitoring. For patients at high risk for blood clots, avatrombopag may be more appropriate as the first-line drug.

In terms of clinical selection, doctors will make individualized medication decisions based on the patient's underlying disease, severity of thrombocytopenia, liver function status, and past drug use. For patients with chronic liver disease who require a rapid increase in platelets for surgery or invasive procedures, avatrombopag is often preferred due to its rapid onset of action and ease of oral administration. For ITP patients with long-term platelet stability, hetrombopag can also be used as an alternative, but platelet changes and potential risks need to be closely monitored. Taken together, both have their own advantages and need to be chosen scientifically based on the specific conditions of the patient.

Reference materials:https://www.drugs.com/